CLINICAL_TRIALS
trial_result
· 2025-12-12
Clinical Trial Update: ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL [Phase 2]
Summary
Phase 2 study of abemaciclib with endocrine therapy, with or without paclitaxel, in aggressive HR+/HER2- metastatic breast cancer has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: MedSIR | Conditions: Breast Cancer Metastatic | Phase 2 | Status: COMPLETED